A trial of nab-paclitaxel and gemcitabine for cancer of the pancreas that has spread (SIEGE)
Cancer type:
Status:
Phase:
This trial looked at 2 different ways of having nab-paclitaxel and gemcitabine chemotherapy for pancreatic cancer that has spread to another part of the body.
More about this trial
- both treatments on the same day – this is called concomitant treatment, and was the standard way to have treatment
- nab-paclitaxel first and then gemcitabine 24 hours later – this is called sequential treatment, and was a new way of having treatment
- see which way of having nab-paclitaxel and gemcitabine works best for pancreatic cancer that has spread
- learn more about how nab-paclitaxel works
Summary of results
- 75 people had both treatments on the same day (concomitant treatment)
- 71 people had nab-paclitaxel first and gemcitabine the next day (sequential treatment)
- 4.1 months for people who had the two treatments together
- 5.8 months for people who had nab-paclitaxel first
- 7.9 months for those who had the two treatments together
- 10.1 months for those who had nab-paclitaxel first
- 20 people who had the two treatments together
- 21 people who had nab-paclitaxel first
- a drop in white blood cells, a drop in red blood cells and tiredness, which affected more people who had nab-paclitaxel first and then gemcitabine
- fever associated with a drop in white blood cells, which affected the same number of people in each group
- being sick, which affected a few more people who had both treatments at the same time

Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Pippa Corrie
Supported by
Cambridge University Hospitals NHS Foundation Trust
Celgene
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Cancer Research UK Cambridge Institute
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040